6098
K. L. Wilkinson et al. / Tetrahedron 60 (2004) 6091–6100
3.80–3.62 (2H, m, H1), 3.45 (1H, m, H4), 1.80–1.25 (9H,
m, H2,3,5,6,7), 1.09 (9H, s, tBu), 0.93 (3H, t, J¼6.0 Hz, H8),
0.89 (3H, d, J¼6.6 Hz, H9); dC (CDCl3) 135.6, 133.5, 129.6,
127.6, 75.7, 62.0, 35.9, 34.5, 33.8, 28.2, 26.8, 22.8, 19.1,
16.2, 14.1.
9.48%]. To this mixture (159 mg, 0.241 mmol) was added
TEMPO (50 mg, 0.32 mmol) and BAIB (200 mg,
0.6 mmol) in acetonitrile (2 mL) and water (3 mL).22
After stirring at room temperature for 48 h, the reaction
mixture was extracted with ethyl acetate (2£30 mL) and the
extracts washed with 5% citric acid solution (15 mL) and
water (15 mL), before being dried and concentrated to give
an orange oil. The crude product was purified by column
chromatography (2% methanol in dichloromethane) to give
(3R,4S) and (3S,4R) 3-methyl-4-O-(20,30,40,60-tetrapivaloyl-
b-D-glucopyranosyl)octanoic acid (10) as a pale yellow
resin (132 mg, 81%).
4.2.5. (3R,4S) and (3S,4R) 1-t-Butyldiphenylsilyloxy-3-
methyl-4-O-(20,30,40,60-tetrapivaloyl-b-D-glucopyrano-
syl)octane (9). The alcohol (^8) (2.83 g, 7.1 mmol) was
glycosylated in an identical manner to that described above
for the cis-species, using 2,3,4,5-tetra-O-pivaloyl-a-D-
glucopyranosyl bromide (4.11 g, 7.1 mmol), silver triflate
(1.824 g, 7.1 mmol) and 2,6-lutidine (820 mL, 7.1 mmol).
The crude product was purified by column chromatography
(10% ethyl acetate in hexane) to give a colourless resin
(4.2 g, 66%). [Found: C, 68.5; H 9.2. C51H80O11Si requires
C, 68.27; H 8.99%]; The individual glycoside diastereomers
were separated in an identical manner to that described for 6.
4.3.1. (3R,4S) 3-Methyl-4-O-(20,30,40,60-tetrapivaloyl-b-D-
glucopyranosyl)octanoic acid (10). Conversion of (3R,4S)-
9 (144.0 mg, 0.16 mmol) into the acid (3R,4S)-10 was
accomplished as outlined above to give a colourless oil
(87.0 mg, 80%); dH (CDCl3) 5.31 (1H, dd, J¼9.4, 9.0 Hz,
0
0
H3 ), 5.11 (1H, dd, J¼9.8, 9.4 Hz, H4 ), 5.03 (1H, dd, J¼9.4,
0
0
Compound (3R,4S)-9. dH (CDCl3) 7.68–7.62 (4H, m, ArH),
0
7.8 Hz, H2 ), 4.61 (1H, d, J¼7.8 Hz, H1 ), 4.22 (1H, br d,
0
0
7.48–7.35 (6H, m, ArH), 5.26 (1H, dd, J¼9.3, 9.3 Hz, H3 ),
J¼12.2 Hz, H6a ), 3.97 (1H, dd, J¼12.2, 5.3 Hz, H6b ), 3.66
0
0
(1H, m, H5 ), 3.50 (1H, m, H4), 2.6–2.46 (1H, m, H2a),
5.10 (1H, dd, J¼9.3, 9.3 Hz, H4 ), 5.01 (1H, dd, J¼9.3,
0
0
7.8 Hz, H2 ), 4.50 (1H, d, J¼7.8 Hz, H1 ), 4.18 (1H, dd,
2.18–1.96 (2H, m, H2b,3), 1.50–1.10 (6H, m, H5,6,7) 1.20,
1.15, 1.14, 1.10 (36H, 4s, CMe3), 0.91 (3H, d, J¼6.3 Hz,
H9), 0.85 (3H, t, J¼7.1 Hz, H8); ESI-MS (80% MeOH)
695.4 (MþNaþ).
4.3.2. (3S,4R) 3-Methyl-4-O-(20,30,40,60-tetrapivaloyl-b-D-
glucopyranosyl)octanoic acid (10). (3S,4R)-9 (202.2 mg,
0.23 mmol) was treated as outlined above to give the acid
(3S,4R)-10 as a colourless oil (113.9 mg, 75%); dH (CDCl3):
0
0
J¼12.0, 1.8 Hz, H6a ), 3.93 (1H, dd, J¼12.0, 5.1 Hz, H6b ),
0
3.72–3.44 (4H, m, H1,4,5 ), 1.58–1.48 (1H, m, H3), 1.48–
1.20 (8H, m, H2,5,6,7), 1.20, 1.14, 1.14, 1.11 (36H, 4s,
COCMe3), 1.06 (9H, s, SiCMe3), 0.84 (3H, t, J¼6.9 Hz, H8),
0.79 (3H, d, J¼6.9 Hz, H9). dC (CDCl3) 178.0, 177.2, 176.4,
176.3, 135.5, 134.0, 129.7, 127.7, 99.4, 82.1, 72.9, 71.8,
71.6, 68.1, 61.8, 61.8, 38.8, 38.7, 38.7, 35.2, 32.0, 29.2,
27.9, 27.3, 27.2, 27.0, 27.0, 26.9, 22.6, 14.5, 14.0; ESI-MS
(80% MeOH) 919.8 (MþNaþ).
0
5.29 (1H, dd, J¼9.5, 9.5 Hz, H3 ), 5.09 (1H, dd, J¼9.5,
0
0
9.3 Hz, H4 ), 4.98 (1H, dd, J¼9.5, 7.9 Hz, H2 ), 4.57 (1H, d,
0
0
Compound (3S,4R)-9. dH (CDCl3) 7.68–7.62 (4H, m, ArH),
0
J¼7.9 Hz, H1 ), 4.23 (1H, br d, J¼12.0, H6a ), 3.94 (1H, dd,
0
0
7.44–7.33 (6H, m, ArH), 5.29 (1H, dd, J¼9.6, 9.3 Hz, H3 ),
J¼12.0, 5.5 Hz, H6b ), 3.66 (1H, m, H5 ), 3.47 (1H, m, H4),
2.42–2.32 (1H, m, H2a), 2.24–1.95 (2H, m, H2b,3), 1.50–
1.10 (6H, m, H5,6,7), 1.19, 1.12, 1.12, 1.08 (36H, 4s, CMe3),
0.94 (3H, d, J¼6.5 Hz, H9), 0.87 (3H, t, J¼6.7 Hz, H8); ESI-
MS (80% MeOH) 695.4 (MþNaþ).
0
5.07 (1H, dd, J¼9.9, 9.6 Hz, H4 ), 4.99 (1H, dd, J¼9.3,
0
0
7.8 Hz, H2 ), 4.56 (1H, d, J¼7.8 Hz, H1 ), 4.21 (1H, dd,
0
0
J¼12.3, 1.8 Hz, H6a ), 3.92 (1H, dd, J¼12.3, 6.0 Hz, H6b ),
0
3.76–3.58 (3H, m, H1,5 ), 3.48 (1H, m, H4), 1.90–1.20 (9H,
m, H2,3,5,6,7), 1.18, 1.14, 1.14, 1.11 (36H, 4s, COCMe3),
1.03 (9H, s, SiCMe3), 0.88 (3H, t, J¼6.6 Hz, H8), 0.82 (3H,
d, J¼6.6 Hz, H9); dC (CDCl3) 178.0, 177.2, 176.5, 176.3,
135.5, 134.0, 129.5, 127.6, 99.0, 82.6, 72.6, 71.9, 71.6, 68.3,
62.2, 62.0, 38.8, 38.7, 38.7, 33.7, 32.3, 30.4, 28.2, 27.2,
27.2, 27.1, 27.0, 26.9, 22.9, 15.8, 14.0; ESI-MS (80%
MeOH) 919.8 (MþNaþ).
4.3.3. (3R,4S) 3-Methyl-4-O-b-D-glucopyranosyloctanoic
acid (3). Protected glycoside (3R,4S)-10 (87.0 mg,
0.13 mmol) was converted into the free glycoside according
to the procedure outlined above, but omitting the second
KOH step, to give (3R,4S)-3 (43.5 mg, 100%); dH
0
(CD3OD): 4.33 (1H, d, J¼7.7 Hz, H1 ), 3.85 (1H, dd,
0
0
)
J¼11.7, 2.4 Hz, H6a ), 3.69 (1H, dd, J¼11.7, 5.2 Hz, H6b
0
0
0
0
4.3. General procedure for deprotection and oxidation
of 9
3.57 (1H, app. q, H4), 3.39–3.16 (4H, m, H2 ,3 ,4 ,5 ), 2.54
(1H, dd, J¼14.6, 4.6 Hz, H2a), 2.26 (1H, m, H3), 2.14 (1H,
dd, J¼14.6, 8.8 Hz, H2b), 1.62–1.24 (6H, m, H5,6,7), 0.99
(3H, d, J¼6.7 Hz, H9), 0.92 (3H, t, J¼7.2 Hz, H8); dC
(CD3OD): 178.4, 105.0, 85.0, 79.0, 78.5, 76.2, 72.6, 63.7,
39.3, 35.4, 32.9, 29.1, 24.6, 16.8, 15.3; ESI-MS (80%
MeOH) 359.4 (MþNaþ); [a]D¼215.5 (c 0.52, CH3OH).
TBAF (230 mg, 0.72 mmol) was added to a solution of
(3R,4S) and (3S,4R)-9 (540 mg, 0.6 mmol) in THF (20 mL)
and stirred at room temperature for 16 h during which time
the solution became yellow in colour. The solvent was
evaporated and the residue dissolved in ethyl acetate
(30 mL) and washed with saturated sodium bicarbonate
solution (10 mL), 5% citric acid solution (10 mL) and water
(2£10 mL). The organic phases were dried and concentrated
and the crude product was purified by column chroma-
tography (10% ethyl acetate0in0hexane) to give (3R,4S) and
(3S,4R) 3-methyl-4-O-(20,3 ,4 ,60-tetrapivaloyl-b-D-gluco-
pyranosyl)octan-1-ol as a colourless oil (230 mg, 87%).
[Found: C 63.9; H 9.3. C35H62O11 requires C, 63.80; H
4.3.4. (3S,4R) 3-Methyl-4-O-b-D-glucopyranosyloctanoic
acid (3). Protected glycoside (3S,4R)-10 (113.9 mg,
0.17 mmol) was converted into the free glycoside according
to the procedure outlined above, to give (3S,4R)-3 (55.9 mg,
0
98%); dH (CD3OD): 4.30 (1H, d, J¼7.7 Hz, H1 ), 3.86 (1H,
0
dd, J¼11.8, 2.2 Hz, H6a ), 3.68 (1H, dd, J¼11.8, 5.3 Hz,
0
0
0
0
0
H6b ) 3.58 (1H, app. q, H4), 3.40–3.14 (4H, m, H2 ,3 ,4 ,5 ),
2.59 (1H, dd, J¼15.3, 5.0 Hz, H2a), 2.24 (1H, m, H3), 2.10